According to Fortune Business Insights, the global swine vaccines market size was valued at USD 1.85 billion in 2025. The market is projected to grow from USD 1.98 billion in 2026 to USD 3.44 billion by 2034, exhibiting a CAGR of 7.15% during the forecast period from 2026 to 2034. Rising prevalence of infectious diseases among swine, increasing adoption of preventive animal healthcare, and growing development of advanced vaccines are supporting market expansion.

Market Overview

The global swine vaccines market is driven by the continuing need for disease prevention across commercial pig farms. Vaccine manufacturers are expanding beyond conventional products by developing combination vaccines, recombinant technologies, advanced antigen designs, and novel delivery platforms.

The market encompasses modified-live attenuated vaccines, inactivated vaccines, bacterins and toxoid-based vaccines, recombinant subunit and virus-like particle vaccines, viral-vector and chimeric vaccines, and newer nucleic-acid and replicon technologies.

The industry is also becoming increasingly connected with digital animal-health systems. Electronic animal identification, digital traceability, herd-health monitoring, and needle-free vaccination technologies are helping producers and veterinarians improve vaccination accuracy and monitor health outcomes.

For detailed market insights: https://www.fortunebusinessinsights.com/swine-vaccines-market-118648

Market Trends

Digital and Precision Vaccination

A significant trend in the swine vaccines market is the integration of vaccination with digital herd-management technologies. Digital identification, traceability, vaccination records, and monitoring systems enable producers to track individual animals and evaluate vaccination effectiveness.

For example, MSD Animal Health showcased its “Swine Protect & Connect” approach in 2025, integrating an intradermal vaccine with needle-free vaccination devices and digital identification and monitoring technology. Such developments demonstrate the industry's movement toward connected and data-driven preventive healthcare.

Diversification of Vaccine Platforms

Manufacturers are increasingly developing combination vaccines, recombinant vaccines, advanced antigen designs, and novel delivery technologies. These platforms can provide broader strain coverage and simplify vaccination schedules.

The nucleic-acid and replicon vaccines segment is expected to record a 14.21% CAGR during the forecast period, highlighting the growing interest in newer vaccine technologies.

Market Drivers

Persistent Burden of Swine Diseases

The persistent prevalence and economic impact of swine diseases remain the leading growth driver. PRRS, porcine circovirus-associated diseases, Mycoplasma hyopneumoniae, swine dysentery, and other respiratory and gastrointestinal infections can cause mortality, reproductive losses, slower weight gain, increased treatment expenses, and lower feed efficiency.

As a result, commercial producers are increasingly relying on preventive vaccination to limit disease transmission and protect productivity. Continued pathogen evolution and changing disease epidemiology are also encouraging manufacturers to develop vaccines with broader coverage.

Expansion of Commercial Swine Production

Growing commercial pig production in emerging markets is creating additional demand for preventive animal-health products. Increasing vaccination coverage across Asia, Latin America, and Africa is opening opportunities for manufacturers, particularly as governments and producers strengthen disease-control programs.

Government Disease-Control Programs

Government-supported vaccination programs and organized disease-control initiatives are creating opportunities for vaccine manufacturers. The expansion of locally produced vaccines, government-funded procurement, and cross-border vaccine supplies can improve accessibility in previously underserved markets.

At the same time, herd contraction, disease-related depopulation, affordability pressures, regulatory complexity, and inconsistent veterinary access can restrain market growth.

Market Segmentation

By Technology

The market is segmented into modified-live attenuated vaccines, inactivated/killed vaccines, bacterins and toxoid-based vaccines, recombinant subunit and virus-like particle vaccines, viral-vector and chimeric vaccines, nucleic-acid and replicon vaccines, and others.

The modified-live attenuated vaccines segment dominated the market in 2025. Their established use against important viral diseases, particularly PRRS, and their ability to stimulate both humoral and cell-mediated immune responses support their leading position.

By Disease Indication

The market includes porcine reproductive and respiratory syndrome, porcine circovirus-associated diseases, Mycoplasma-associated enzootic pneumonia, swine influenza, enteric diseases, reproductive diseases, systemic and bacterial diseases, transboundary and notifiable diseases, and others.

The porcine reproductive and respiratory syndrome segment held the leading market share in 2025, supported by the disease's widespread occurrence, economic impact, and complex epidemiology. The transboundary and notifiable diseases segment is expected to grow at a 9.99% CAGR during 2026–2034.

By Route of Administration

The market is divided into intramuscular, intradermal, oral, subcutaneous, and other routes.

The intramuscular segment dominated in 2025, supported by its established role in commercial vaccination protocols and broad availability of licensed products. Meanwhile, the intradermal segment is expected to expand at a 10.56% CAGR through 2034 as needle-free and convenient administration technologies gain adoption.

By Distribution Channel

Distribution channels include direct sales to integrated swine producers, veterinary distributors and wholesalers, veterinarian-led and animal-health service channels, agro-veterinary retailers and cooperatives, government and public procurement, and others.

Direct sales to integrated swine producers led the market in 2025 because large commercial producers require recurring, standardized vaccination programs and technical support. Government and public procurement is projected to grow at an 8.96% CAGR during the forecast period.

Key Players

Major companies operating in the global swine vaccines market include Boehringer Ingelheim International GmbH, Zoetis Inc., Merck & Co., Inc., Ceva Santé Animale S.A., Laboratorios HIPRA, S.A., Jinyu Bio-Technology Co., Ltd., Elanco Animal Health Incorporated, China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc., Tianjin Ringpu Bio-Technology Co., Ltd., Vaxxinova International B.V., Phibro Animal Health Corporation, Qilu Animal Health Products Co., Ltd., Biogénesis Bagó S.A., and Bioveta, a.s.

Regional Analysis

Asia Pacific dominated the global swine vaccines market in 2025 and is estimated to reach USD 0.78 billion in 2026. The region benefits from its large pig population, recurring disease outbreaks, and modernization of commercial pig farming. China is projected to generate approximately USD 0.43 billion in 2026, while India's market is estimated at around USD 0.04 billion.

North America held the second-largest position, with the market valued at USD 0.54 billion in 2025. High prevalence of PRRS, PCV2, influenza, and other endemic diseases, combined with strong commercial farming practices and veterinary spending, supports regional demand. The U.S. market is estimated at USD 0.50 billion in 2026.

Europe is projected to grow at a 5.97% CAGR, reaching approximately USD 0.43 billion in 2026. Preventive animal healthcare, biosecurity, disease surveillance, combination vaccines, and intradermal technologies are supporting regional growth.

Latin America is expected to experience moderate growth, reaching approximately USD 0.18 billion in 2026, supported by export-oriented pork production and increasing herd-health investments. The Middle East & Africa region is also expanding as veterinary infrastructure and disease-control initiatives develop.

Competitive Landscape

The global swine vaccines market is moderately fragmented, with multinational animal-health companies competing alongside established regional manufacturers. Major companies are strengthening their positions through vaccine innovation, portfolio diversification, geographic expansion, acquisitions, and strategic collaborations.

Competition is increasingly focused on broader strain coverage, combination vaccines, digital technologies, advanced delivery systems, and integrated disease-prevention solutions. Elanco, for example, highlighted AI-powered immunoinformatics research in 2026 to evaluate potential PRRSV vaccine protection against circulating viral strains.

Recent industry developments also include the approval of AVAC ASF LIVE for commercial sale in the Philippines, HIPRA's initiatives focused on PRRS management, and expansion of African swine fever vaccine commercialization across Asian markets.

Future Outlook

The future of the swine vaccines market will be shaped by rising disease pressure, expansion of commercial pig farming, greater vaccination coverage, and continued innovation in vaccine technology. Combination vaccines, recombinant platforms, needle-free administration, digital monitoring, and data-driven herd-health management are expected to gain greater importance.

Government disease-control programs and the development of vaccines for transboundary diseases such as African swine fever could provide significant opportunities. At the same time, manufacturers will need to address cold-chain limitations, uneven veterinary access, affordability, regulatory requirements, and differences in pathogen strains across regions.

Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/swine-vaccines-market-118648

Conclusion

The global swine vaccines market is expanding as commercial producers increasingly prioritize preventive animal healthcare and disease control. Valued at USD 1.85 billion in 2025, the market is projected to reach USD 3.44 billion by 2034, growing at a 7.15% CAGR from 2026 to 2034.

Asia Pacific will remain a major market due to its large swine population and expanding commercial production, while North America and Europe will continue to benefit from advanced vaccination practices. Technological innovation, digital vaccination systems, broader disease coverage, and government-supported disease-control programs are expected to create new opportunities throughout the forecast period.

Latest 5 Trending FAQs

1. What is the global swine vaccines market size?

According to Fortune Business Insights, the global swine vaccines market was valued at USD 1.85 billion in 2025 and is projected to reach USD 3.44 billion by 2034.

2. What will be the swine vaccines market size in 2026?

The global swine vaccines market is projected to reach USD 1.98 billion in 2026.

3. What is the CAGR of the swine vaccines market?

The market is expected to grow at a CAGR of 7.15% from 2026 to 2034.

4. Which technology segment is expected to lead the swine vaccines market?

The modified-live attenuated vaccines segment is expected to lead the market by technology, supported by its established use against major swine diseases, particularly PRRS.

5. Which region accounted for the largest share of the swine vaccines market in 2025?

Asia Pacific dominated the global swine vaccines market in 2025, with the regional market valued at USD 0.72 billion.

Curious About Japan’s Market? Explore the Latest Swine Vaccines Market Insights